Latigo Biotherapeutics (NASDAQ:LTGO) Upgraded at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Latigo Biotherapeutics (NASDAQ:LTGO – Free Report) from a sell rating to a hold rating in a report published on Saturday,Wall Street Zen reports.

Several other research analysts have also commented on the company. Jefferies Financial Group assumed coverage on Latigo Biotherapeutics in a research report on Tuesday, September 1st. They issued a “buy” rating and a $50.00 price target for the company. The Goldman Sachs Group started coverage on Latigo Biotherapeutics in a research report on Tuesday, September 1st. They set a “buy” rating and a $73.00 price objective on the stock. Guggenheim began coverage on Latigo Biotherapeutics in a research note on Tuesday, September 1st. They issued a “buy” rating and a $50.00 price objective for the company. Finally, Leerink Partners began coverage on Latigo Biotherapeutics in a report on Tuesday, September 1st. They issued an “outperform” rating and a $36.00 target price for the company. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Latigo Biotherapeutics presently has a consensus rating of “Buy” and an average price target of $52.25.

Read Our Latest Research Report on Latigo Biotherapeutics

Latigo Biotherapeutics Price Performance

Shares of NASDAQ:LTGO opened at $17.48 on Friday. Latigo Biotherapeutics has a 52 week low of $16.19 and a 52 week high of $25.93.

Latigo Biotherapeutics (NASDAQ:LTGO – Get Free Report) last posted its earnings results on Thursday, September 3rd. The company reported ($27.59) earnings per share for the quarter.

Insider Activity

In other news, major shareholder Foresite Capital Management V, acquired 140,000 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was acquired at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the purchase, the insider directly owned 2,008,024 shares in the company, valued at approximately $36,144,432. This trade represents a 7.49% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James Tananbaum bought 140,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were acquired at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the transaction, the director directly owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. This trade represents a 7.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Latigo Biotherapeutics Company Profile

(Get Free Report)

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid medicines for the treatment of acute and chronic pain. The company focuses on selectively targeting Nav1.8, a sodium channel involved in the transmission of pain signals, with the goal of developing therapies that may provide pain relief without the risks associated with opioid medications.

Latigo’s pipeline includes small-molecule Nav1.8 inhibitors, led by LTG-001 for acute pain and additional research programs aimed at chronic pain conditions.

See Also